OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press18110.17650/1818-8346-2016-11-1-47-51HEMATOPOIETIC STEM CELL TRANSPLANTATIONТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК У ПАЦИЕНТОВ С ГЕМОБЛАСТОЗАМИExtracorporeal photopheresis in the treatment of graft-versus-host diseaseЭкстракорпоральный фотоферез в лечении реакции «транспл антат против хозяина»GuzI. V.ГузИ. В.
Russian Federation
ilikis@mail.ruTrachtmanP. E.ТрахтманП. Е.
Russian Federation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health of RussiaФГБУ «ФНКЦ ДГОИ им. Дмитрия Рогачева» Минздрава России1 Samory Mashela St., Moscow, 117198, RussiaРоссия, 117997, Москва, ул. Саморы Машела, 13103201611147513103201631032016https://oncohematology.abvpress.ru/ongm/article/view/181

Extracorporeal photopheresis has proved efficacy in the treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation and is an alternative to other treatments. This method is characterized by good tolerability, the lack of age restrictions, minimum of infectious complications compared to increasing immunosuppression. This therapy gives a real improvement in the quality of life.

Экстракорпоральный фотоферез доказал свою практическую эффективность в лечении хронической реакции «трансплантат против хозяина» после аллогенной трансплантации гемопоэтических стволовых клеток и представляет собой альтернативу другим методам лечения. К его преимуществам относятся хорошая переносимость, отсутствие ограничений по возрасту, минимум инфекционных осложнений по сравнению с последствиями увеличения иммуносупрессии. Этот метод терапии дает реальное улучшение качества жизни.

allogeneic hematopoietic stem cell transplantationextracorporeal photopheresisgraft-versus-host disease8-methoxypsoralenаллогенная трансплантация гемопоэтических стволовых клетокэкстракорпоральный фотоферезреакция «трансплантат против хозяина»8-метоксипсорален1. Hart J. W., Shiue L. H., Shpall E. J., Alousi A. M. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol 2013;4(5):320–34.Hart J. W., Shiue L. H., Shpall E. J., Alousi A. M. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol 2013;4(5):320–34.2. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007;20(2):281–94.Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007;20(2):281–94.3. Worel N., Leitner G. Clinical results of extracorporeal photopheresis. Transfus Med Hemother 2012;39(4):254–62.Worel N., Leitner G. Clinical results of extracorporeal photopheresis. Transfus Med Hemother 2012;39(4):254–62.4. Yoo E. K., Rook A. H., Elenitsas R. et al. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996;107(2):235–42.Yoo E. K., Rook A. H., Elenitsas R. et al. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996;107(2):235–42.5. Berger C. L., Xu A. L., Hanlon D. et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001;91(4):438–47.Berger C. L., Xu A. L., Hanlon D. et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001;91(4):438–47.6. Knobler R., Berlin G., Calzavara-Pinton P. et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 2014;28 Suppl 1:1–37.Knobler R., Berlin G., Calzavara-Pinton P. et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 2014;28 Suppl 1:1–37.7. Edelson R. L. Photopheresis: a clinically relevant immunobiologic response modifier. Ann NY Acad Sci 1991;636:154–64.Edelson R. L. Photopheresis: a clinically relevant immunobiologic response modifier. Ann NY Acad Sci 1991;636:154–64.8. Steinman R. M., Turley S., Mellman I., Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191(3):411–6.Steinman R. M., Turley S., Mellman I., Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191(3):411–6.9. Stewart B. L., Storer B., Storek J. et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004;104(12):3501–6.Stewart B. L., Storer B., Storek J. et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004;104(12):3501–6.10. Lee S. J., Vogelsang G., Flowers M. E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9(4):215–33.Lee S. J., Vogelsang G., Flowers M. E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9(4):215–33.11. Carlens S., Ringden O., Remberger M. et al. Risk factors for chronic graft-versushost disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998;22(8):755–61.Carlens S., Ringden O., Remberger M. et al. Risk factors for chronic graft-versushost disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998;22(8):755–61.12. Anasetti C., Logan B. R., Lee S. J. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367(16):1487–96.Anasetti C., Logan B. R., Lee S. J. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367(16):1487–96.13. Owsianowski M., Gollnick H., Siegert W. et al. Successful treatment of chronic graftversus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994;14(5):845–8.Owsianowski M., Gollnick H., Siegert W. et al. Successful treatment of chronic graftversus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994;14(5):845–8.14. Flowers M. E., Inamoto Y., Carpenter P. A. et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117(11):3214–9.Flowers M. E., Inamoto Y., Carpenter P. A. et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117(11):3214–9.15. Flowers M. E., Apperley J. F., van Besien K. et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008;112(7):2667–74.Flowers M. E., Apperley J. F., van Besien K. et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008;112(7):2667–74.16. Malik M. I., Litzow M., Hogan W. et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res 2014;49(2):100–6.Malik M. I., Litzow M., Hogan W. et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res 2014;49(2):100–6.17. Hahn T., McCarthy P. L. Jr, Zhang M. J. et al. Risk factors for acute graft-versus-host disease after human leukocyte antigenidentical sibling transplants for adults with leukemia. J Clin Oncol 2008;26(35): 5728–34.Hahn T., McCarthy P. L. Jr, Zhang M. J. et al. Risk factors for acute graft-versus-host disease after human leukocyte antigenidentical sibling transplants for adults with leukemia. J Clin Oncol 2008;26(35): 5728–34.18. Bolaños-Meade J., Vogelsang G. B. Novel strategies for steroid-refractory acute graftversus-host disease. Curr Opin Hematol 2005;12(1):40–4.Bolaños-Meade J., Vogelsang G. B. Novel strategies for steroid-refractory acute graftversus-host disease. Curr Opin Hematol 2005;12(1):40–4.19. Wolff D., Ayuk F., Elmaagacli A. et al. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant 2013;19(5):767–76.Wolff D., Ayuk F., Elmaagacli A. et al. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant 2013;19(5):767–76.20. Deeg H. J. How I treat refractory acute GVHD. Blood 2007;109(10):4119–26.Deeg H. J. How I treat refractory acute GVHD. Blood 2007;109(10):4119–26.21. Greinix H. T., Knobler R. M., Worel N. et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006;91(3):405–8.Greinix H. T., Knobler R. M., Worel N. et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006;91(3):405–8.22. Greinix H. T., Worel N., Knobler R. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft- versus-host disease. Biol Blood Marrow Transplant 2010;16(12):1747–8.Greinix H. T., Worel N., Knobler R. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft- versus-host disease. Biol Blood Marrow Transplant 2010;16(12):1747–8.23. Zhang H., Chen R., Cheng J. et al. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. Patient Prefer Adherence 2015;9:105–11.Zhang H., Chen R., Cheng J. et al. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. Patient Prefer Adherence 2015;9:105–11.24. Kanold J., Merlin E., Halle P. et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007;47(12):2276–89.Kanold J., Merlin E., Halle P. et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007;47(12):2276–89.25. Calore E., Calò A., Tridello G. et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008;42(6):421–5.Calore E., Calò A., Tridello G. et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008;42(6):421–5.26. Messina C., Locatelli F., Lanino E. et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003;122(1):118–27.Messina C., Locatelli F., Lanino E. et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003;122(1):118–27.27. Klassen J. The role of photopheresis in the treatment of graft-versus-host disease. Curr Oncol 2010;17(2):55–8.Klassen J. The role of photopheresis in the treatment of graft-versus-host disease. Curr Oncol 2010;17(2):55–8.28. Couriel D., Hosing C., Saliba R. et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006;107(8):3074–80.Couriel D., Hosing C., Saliba R. et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006;107(8):3074–80.29. Foss F., Gorgun G., Miller K. Extracorporeal photopheresis in chronic graft-versushost disease. Bone Marrow Transplant 2002;29(9):719–25.Foss F., Gorgun G., Miller K. Extracorporeal photopheresis in chronic graft-versushost disease. Bone Marrow Transplant 2002;29(9):719–25.